A new kind of drug, a Raf kinase inhibitor, is well-tolerated and may prove effective in treating patients with metastatic melanoma, according to researchers from the Abramson Cancer Center of the University of Pennsylvania.
Reviewing Late-Breaking Research From AAD 2024
ReV Up Your Vitiligo Treatment Strategies
Amy Spizuoco, DO, FAOCD: Addressing STDs and Utilizing Dermatopathology With Care in Diverse Patient Populations
The Cutaneous Connection: Splish, Splash, AD Management Starts in the Bath
Melanoma and the Wrong Site
Tunlametinib Wins Approval in China for NRAS+ Advanced Melanoma After PD-1/PD-L1 Therapy